Log in to search using one of your social media accounts:


Swinging at Lou Gehrig's disease, Peninsula drug maker strikes out

After spending "hundreds of millions" of dollars over eight years on an experimental drug for people with amyotrophic lateral sclerosis, or ALS, a South San Francisco company's late-stage trial came up short.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news

Related Links:

More News: ALS | Biotechnology | Health Management